Johnson & Johnson (NY:JNJ)

The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes.

The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning ↗

September 23, 2025

Via Benzinga

Jabil Set For Major AI Growth As Other Segments Falter: Analyst ↗

September 23, 2025

Jabil Inc. to report fiscal Q4 earnings; AI and cloud revenue key factors for outlook. Analyst expects conservative guidance.

Via Benzinga

Topics Artificial Intelligence

Evolving Investment Strategies for an Uncertain Market

September 23, 2025

In an era marked by persistent inflation, fluctuating interest rates, geopolitical tensions, and rapid technological shifts, investors are facing an increasingly complex and unpredictable financial...

Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish ↗

Topics Bonds ETFs Economy

September 22, 2025

Johnson & Johnson will halt international sales of its Linx reflux device, sparking concern among surgeons over limited options for GERD patients.

Topics Government

This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

September 23, 2025

Via Benzinga

Johnson & Johnson Ends Overseas Sales Of Acid Reflux Device Citing Market Factors ↗

September 23, 2025

Via Benzinga

Beyond The Numbers: 10 Analysts Discuss Johnson & Johnson Stock ↗

September 23, 2025

Via Benzinga

The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now ↗

September 23, 2025

This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety?

Jim Cramer Says Trump Is Creating 'A Nightmare' For Kenvue As President Links Tylenol With Autism ↗

September 23, 2025

Jim Cramer says Trump creates a "nightmare" for Kenvue after linking Tylenol to autism. Learn why KVUE stock is plunging amid lawsuit fears.

Via Benzinga

Topics Government Lawsuit

Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check? ↗

September 23, 2025

Guggenheim’s upgrade and new data on J&J’s experimental depression drug helped steady sentiment, even as investors weighed political scrutiny and ongoing litigation risks.

U.S. Government Shutdown Looms: A Guide for Investors Navigating Political and Economic Uncertainty

Topics Government

September 22, 2025

As the perennial specter of a U.S. government shutdown once again casts a shadow over Washington, D.C., financial markets are bracing for potential turbulence. The failure of Congress to agree on...

The latest controversy poses a new reputational challenge for Kenvue, which was spun out of Johnson & Johnson in 2023.

Topics Bonds Economy

Kenvue Stock Sinks To Record Low As Trump To Reportedly Link Tylenol Use To Autism ↗

September 22, 2025

Via Talk Markets

Topics Government

The Enduring Appeal of Dividend Aristocrats: A Beacon of Stability in Turbulent Markets

September 22, 2025

In an era marked by fluctuating interest rates, geopolitical uncertainties, and shifting economic landscapes, a select group of companies known as "Dividend Aristocrats" continues to shine as pillars...

In an era of fluctuating financial markets and evolving economic landscapes, the allure of dividend-paying stocks as a cornerstone for building long-term wealth remains as potent as ever. As investors...

Topics ETFs Economy Energy

The Unyielding Power of Dividends: A Blueprint for Enduring Wealth

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Topics Retirement Supply Chain

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance

Topics Artificial Intelligence Economy Intellectual Property

September 22, 2025

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter...

Kenvue, J&J Retail Traders Cautious As US Health Officials Reportedly Plan To Announce Tylenol Links To Autism ↗

Topics Artificial Intelligence Intellectual Property

September 22, 2025

Tylenol is one of the most common medicines for reducing pain and fever, and a major product for Kenvue.

The trillion-dollar club will probably need to make room for at least one Dividend King in the coming years.

Topics Government

Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years? ↗

September 21, 2025

Ben & Jerry's Co-Founder Resigns In Protest As Politics Continue To Influence Corporate Exits ↗

Topics Artificial Intelligence Intellectual Property

September 20, 2025

Jerry Greenfield, of Ben & Jerry's fame, didn't resign over personal controversy—he quit because his company stopped being political enough.

Via Benzinga

What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill ↗

September 20, 2025

A high yield is only one part of the story when it comes to picking dividend stocks.

Johnson & Johnson Confronts the End of its Talc Legacy with Multi-Billion Dollar Settlements

Topics Intellectual Property

September 19, 2025

Johnson & Johnson (NYSE: JNJ) is navigating a critical juncture in its protracted legal battle over talc-based baby powder. The healthcare behemoth has announced a tentative $700 million settlement...

Procter & Gamble (NYSE: PG) recently disclosed its fiscal third-quarter 2025 results, presenting a nuanced financial picture that has stirred investor sentiment. While the consumer goods titan managed...

Topics Bankruptcy Death Lawsuit

P&G's Q3 2025: Sales Miss Overshadows Earnings Beat Amidst Global Headwinds

September 19, 2025

Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era

Topics Artificial Intelligence Earnings Economy

September 19, 2025

Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet...

Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a...

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

Topics Artificial Intelligence Economy Government

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients ↗

September 19, 2025

Johnson & Johnson's Tecvayli-Darzalex regimen showed 100% response rates and high MRD negativity in newly diagnosed multiple myeloma patients.

Via Benzinga

Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J? ↗

September 19, 2025

The company is looking to take on Johnson & Johnson in treating patients with a precursor to multiple myeloma.

Via Investor's Business Daily

Recent Report Shows That Rep. Thomas Kean Bought Up to $45K Worth of Amcor Stock ↗

September 19, 2025

Via Benzinga

8 Dividend Growth Stocks Every Investor Should Consider ↗

September 19, 2025

These dividend powerhouses compound wealth through decades of consecutive increases and sustainable payout ratios.